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ABSTRACT
Objective Rheumatoid arthritis (RA) often affects women
in their fertile age, and is known to compromise female
fertility. Serum anti-Müllerian hormone (AMH) levels are
a proxy for the total number of primordial follicles, and
a reliable predictor of the age at menopause. Our objective
was to study the longitudinal intra-individual decline of
serum AMH levels in female RA patients.
Methods Female RA patients from a nationwide
prospective cohort (2002–2008) were re-assessed in
2015–2016. Serum AMH levels were measured using the
picoAMH assay and compared with healthy controls. A linear
mixed model (LMM) was built to assess the effect of RA-
related clinical factors on the decline of AMH levels.
Results A group of 128 women were re-assessed at an age
of 42.6±4.4 years, with a median disease duration of 15.8
(IQR 12.7–21.5) years. The time between first and last AMH
assessments was 10.7±1.8 (range 6.4–13.7) years.
Participants represented a more fertile selection of the
original cohort. At follow-up, 39% of patients had AMH levels
below the 10th percentile of controls (95% CI 31% to 48%),
compared with 16% (95% CI 9.3% to 22%) at baseline. The
LMM showed a significant decline of AMH with increasing
age, but no significant effect of RA-related factors on AMH.
Conclusion AMH levels in RA patients showed a more
pronounced decline over time than expected, supporting the
idea that in chronic inflammatory conditions, reproductive
function is compromised, resulting in a faster decline of ovarian
function over time and probably an earlier age at menopause.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflam-
matory auto-immune disease that often affects
women in their fertile age. RA not only affects
the joints, but can also cause extra-articular
damage, affecting different organ systems.1 2
A prolonged time to pregnancy3 4 and
a younger age at which menopause sets in5 6
are both indicators that in women with RA the
ovarian functionmay be compromised as well.
The ovarian function depends on both the
quantity and the quality of the primordial
follicles in the ovaries. At birth, there are
approximately 1 000 000 primordial follicles
present in the ovaries. This number gradually
decreases over time, resulting in about
300 000 remaining follicles at menarche.7 8
During her twenties and thirties, a woman’s
follicle pool further decreases, with a slight
acceleration in her late thirties and early for-
ties. Finally, the near depletion of the ovarian
follicle pool is marked by the cessation of
menstruation.9 The last menstrual period in
a woman’s life span, that is, the menopause,
occurs at a mean age of 51 years. Infertility
generally sets in approximately 10 years
before a woman experiences menopause.9
This results not only from the decline in num-
ber of developing ovarian follicles over time,
but also from a decrease in quality of the
oocytes maturing within these follicles due to
accumulated damage from birth onwards.10
The age at which a woman reaches meno-
pause, as well as the preceding period of
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Key messages
► Serum anti-Müllerian hormone (AMH) levels are
a proxy for the remaining number of ovarian
primordial follicles, and as such reflect ovarian
function.
► Serum AMH levels in this longitudinal cohort of
female RA patients revealed that levels decreased
more rapidly in patients compared with controls.
► The more rapid decline of serum AMH levels in
women with established RA indicates that chronic
inflammation compromises ovarian function, and
may result in an earlier age at menopause.
► No significant effect of separate RA-related factors
on decline of AMH levels could be identified.
► Optimal treatment of chronic inflammatory
disease in an early phase may improve long-
term women’s health.
Rheumatoid arthritis
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decreased fertility and infertility, varies greatly between
women.9 At present, the serum level of anti-Müllerian
hormone (AMH) is the most reliable predictor for the
age at which a woman will enter menopause.11 Although
prediction of the actual age at menopause based on
a single AMH measurement is still not very precise.11
AMH is a member of the transforming growth factor β
family and is produced in the ovary by granulosa cells of
early developing follicles.12 In both healthy and subfertile
women, there is a strong correlation between serumAMH
levels and the number of developing follicles in the ovar-
ies. It has been shown that serum AMH levels become
undetectable approximately 5 years before a woman
reaches menopause.13
Genes associated with the age of menopause, and more
specifically the length of the reproductive life span of
a woman, are generally involved in DNA repair andmain-
tenance as well as in the immune system.14 In this way,
genes involved in healthy ageing are also predictors for
ovarian function. Indeed, a compromised ovarian func-
tion has been described in patients with type II diabetes
mellitus15 and in young girls with cancer.16 This suggests
that an unhealthy soma results in an early decline of
ovarian function. It is unknown whether the same holds
true for chronic inflammation.14
In womenwith RA, AMH levels at time of diagnosis have
been found to be comparable to those in healthy
controls.17 Furthermore, after 6 months of methotrexate
(MTX) therapy in RA patients, AMH levels did not differ
from those in patients who did not use MTX.17 When
analysing women with established RA, AMH levels were
indeed lower compared with healthy controls.18 19 How-
ever, thus far there have been no longitudinal studies on
AMH levels in RA patients. Nor has the effect of disease
characteristics on the decline of AMH levels over time
been studied.
The objective of the current study was to investigate the
intra-individual change in AMH levels over a longer time
period in women with RA. We compared serum AMH
levels in RA patients with those in controls from the
general population, and studied the decline of serum
AMH levels in RA patients over time in relation to RA-
related clinical factors.
METHODS
Patients
For this observational cohort study, patients were recruited
who had participated in the Pregnancy-induced ameliora-
tion of RA (PARA) study. The PARA study is a nationwide
prospective cohort study, which was performed in the Neth-
erlands in 2002–2010.20 Patients were invited to participate
by their attending rheumatologist if they had a diagnosis of
RA according to the 1987 ACR criteria,21 and if they were
actively trying to conceive or were already pregnant.
Patients had to have a good understanding of the Dutch
language.20 Patients could participate in the PARA study
more than once. For the current follow-up study, patients
were contacted when they had given consent to be con-
tacted for future research, and when they had at least
one non-pregnant serum sample available (ie, from
a preconception visit, or from a visit 6 months postpartum).
The majority of the PARA subjects had been contacted
in 2013–2014 for a questionnaire on fertility.22 As a result,
addresses were up to date whenever possible. Patients
currently living outside of the Netherlands or Belgium
were excluded.
Ethical approval
The original PARA study, as well as the current follow-up
study, were performed according to the Declaration of
Helsinki, and were approved by the Medical Ethics
Review Committee of the Erasmus MC.
Data collection
During the original PARA study,20 patients were visited at
their homes before, during, and after pregnancy, with the
final visit 6 months postpartum. Each assessment con-
sisted of a questionnaire driven interview on disease char-
acteristics and use ofmedication, measurement of disease
activity, and drawing of serum samples.
For the current study, patients received an information
letter, and thereafter were contacted by telephone.
Patients who gave informed consent, were visited at
their home address for blood sampling, and they com-
pleted an online questionnaire including questions on
menstrual cycle, age at menarche, hormone use, and
other possible iatrogenic causes for amenorrhoea, includ-
ing abdominal surgery and chemotherapy.
Measurements
Disease activity wasmeasured during the PARA study visits
using the Disease Activity Score assessing 28 joints
(DAS28) for tenderness and swollenness, combined with
serum C reactive protein levels.23
Serum samples were stored at −80°C. SerumAMH levels
were measured in the samples from all preconception
and 6 month postpartum PARA study assessments, as
well as in the newly acquired samples from the follow-up
visit.
AMH values were measured using the picoAMH assay,
provided by Ansh labs (Houston, Texas, USA).24 25 Inter-
assay and intra-assay coefficients of variation were
both <5%.
Controls
Serum AMH levels in patients were compared with
a group of healthy controls. This international reference
cohort existed of 554 healthy adult women, aged
18–47 years, who had a regular menstrual cycle and/or
were proven fertile.26 AMH levels in controls were origin-
ally reported as measured by the Beckman Coulter Gen II
Assay. Therefore, a conversion factor was used to com-
pare AMH levels in the patient group to those in the
controls25:
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AMH ðpicoAMHassay in ng=mLÞ
¼ ð1:45  AMHGenIIÞ þ 0:32:
Statistical analysis
Values are presented as mean±SD for normally distribu-
ted variables, as median IQR if values were non-normally
distributed, and as number (%) for dichotomous vari-
ables. The number of missing values are given for each
variable.
To approach a normal distribution, AMH levels were
log-transformed for analysis. To correct for different dis-
tributions of ages between patients and controls at the
different time points, AMH levels were compared with
controls using analysis of covariance on log-transformed
AMH levels with adjustment for age.
Sensitivity analyses were performed by excluding
women using combined oral contraceptives, and by
excluding women using any steroid sex hormones.
To reduce potential bias in the longitudinal analysis
due to missing values, multiple imputation was per-
formed. To incorporate the longitudinal outcome into
the imputation procedure, a preliminary linear-mixed
model (LMM) with a random intercept and random
slope was fitted, using only completely observed covari-
ates, and age as time variable. The random intercept and
slope estimated by this model were considered a summary
of the outcome, and were added as predictor variables to
the imputation models.27
To study the effect of RA-related factors (disease dura-
tion, presence of ACPA, presence of RF, presence of
erosions, past use of MTX) on the AMH levels, a LMM
with random intercept and slope was built, using biologi-
cal age as time variable. To obtain a more normal distri-
bution of residuals and random effects in the LMM,
a square root transformation was applied to the AMH
levels. Interactions between ACPA, RF, and erosions,
and between age and disease duration, were considered
in the model. Pooled results from the 10 multiple
imputed datasets are presented.
Since gynaecological age (ie, years since menarche)
may more precisely explain the inter-individual differ-
ence than biological age, a second analysis was performed
using gynaecological age as time variable.
Statistical analysis was performed using Stata SE v14
(College Station, Texas, USA) and R version 3.3.1
(2016, the R foundation for statistical computing;
packages used: mice, lme4).
RESULTS
Patients
Serum samples for 128 patients (43% of the original
PARA cohort) were available for analysis (figure 1). For
two patients no questionnaire data were available for the
latest visit, but they were included in the analyses. Base-
line characteristics are given in table 1.
We compared the 128 study participants to the non-
participating subjects (n=167) of the former PARA cohort
(table 2). There was a significantly lower percentage of
smokers among participants (7%) than in the non-
participants (17%) (p=0.013). Furthermore, nulliparity
was significantly more common among the non-
participants (22%) than in the participants (4.7%) at
the end of their final PARA episode (p<0.001). There
were no significant differences in age, number of epi-
sodes participated in the PARA study, disease duration
during the PARA study or current disease duration, pre-
sence of ACPA or RF, preconception disease activity dur-
ing last PARA episode, or disease activity at the last PARA
visit (either preconception or 6 months postpartum).
Of the participants, 41 (32%) women reported amenor-
rhoea (ie, no menstruation in the preceding 12 months).
In 29 women this could be explained by continuous oral
contraceptive use (n=3) or the presence of a hormonal
intra-uterine device (n=26), and 1 woman had a lactation
amenorrhoea. Seven women had had a hysterectomy. In
four women (3.1%) the amenorrhoea could not be
explained by other causes, and they were considered
postmenopausal. Their menopause had been at an age
of 39, 44, 44 and 45 years, respectively. Three of them had
AMH values below the LoD, and in one patient the serum
AMH level was 0.0114 μg/L.
Hormone measurements
Participant serumAMH levels during follow-up were com-
pared with AMH levels in healthy controls (figure 2). The
mean age in controls was 30.6±7.4 years, with a range of
18.0–46.8 years. The age range for patients at the follow-
up visit was 31.6–53.5 years. Corrected for age, AMH levels
in women with RA at the follow-up visit were significantly
lower than those in controls (p<0.001).
Looking at the age-specific percentiles, 50 RA patients
(39%; 95%CI 31% to 48%) had a serumAMH level below
the 10th percentile, compared with 20 patients (16%;
95% CI 9.3% to 22%) at the first available assessment
(figure 2). At the follow-up assessment, 3 RA patients
were older than 51 years, and as such, their age exceeded
the age range of the nomogram (maximum age 51 years).
In RA patients not using oral contraceptives at the
follow-up assessment (n=100), the percentage of women
with AMH levels below the 10th percentile was 36% (95%
CI 27% to 45%). In patients not using any steroid sex
hormones at follow-up (n=61), this was 33% (95%CI 21%
to 47%).
In table 3, the age-specific AMH percentiles are shown
for all RA patients at the first and last measurement,
grouped by disease characteristics. At the last assessment,
higher percentages of patients with AMH levels below the
10th percentile were seen in ACPA-positive patients vs
ACPA-negative patients, in RF positive patients versus RF
negative patients, and in patients with erosions at baseline
versus those without erosions at baseline. However, these
differences were not statistically significant.
Rheumatoid arthritis
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Linear mixed model
For one patient eight measurements were available, four
patients had seven measurements, one patient had six
measurements, 13 patients had 5 measurements, 50
patients had 4 measurements, 15 patients had 3 measure-
ments and 44 patients had 2 measurements. The intra-
individual mean time between the first available AMH
measurement and the last was 10.7±1.8 years, with
a range of 6.4–13.7 years. The mean age at the first
AMH measurement was 31.8±3.8 years, and at the final
assessment 42.6±4.4 years.
Repeated measurement analysis using an LMM in the
RA patients showed a significant decrease of serum AMH
levels with increasing age. None of the RA-related vari-
ables (disease duration, presence of ACPA, of RF, or of
erosions, MTX use (ever)) did have a significant effect on
the AMH levels over time in this group of 128 female RA
patients (table 4). Comparing the full model shown in
table 4 with a simple model of AMH based on age alone
using a likelihood ratio test, did not reveal any significant
differences, confirming the findings shown in table 4.
The additional analysis with gynaecological age as time
variable, was performed in the 122 patients that reported
their age at menarche. Besides the decline of AMH with
increasing gynaecological age, no other variables did
show a significant effect. The full model based on gynae-
cological age was not significantly different from a simple
model of AMH based on gynaecological age exclusively.
DISCUSSION
Women with RA had a compromised ovarian function
compared with healthy controls, with a considerably
Figure 1 Flow chart showing the patients from the original pregnancy-induced amelioration of rheumatoid arthritis (PARA) study
that did participate in the current study and were available for analysis.
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larger proportion of women with RA having AMH levels
below the age-specific 10th percentile. Assessment of
serum AMH levels over time in female RA patients
revealed that levels decreased more rapidly in patients
compared with controls. Longitudinal analyses did not
show any significant effect of RA-related factors on serum
AMH levels.
The more rapid decline of serum AMH levels over time
in women with established RA may indicate that chronic
inflammation compromises ovarian function. The latter
may even decline faster than was currently found in
women with RA since the participants in this study repre-
sented a more fertile selection, with also less smokers,
than the original PARA cohort. Since the original PARA
cohort was already a relative healthy cohort,20 the true
difference between women with RA and the general
population may be even larger.
The compromised ovarian function in RA may be
a direct effect of cumulative inflammatory damage to
the ovaries. Ovarian ageing and inflammation are
reported to be linked.28 Although we found no sig-
nificant association between disease activity and AMH
levels in current or previous analyses, there is
a relation with ACPA-positivity, which represents
patients with on average more active disease, often
requiring a more intensive treatment strategy.29 We
have previously reported significantly lower serum
AMH levels in ACPA-positive patients,19 and in the
current study more ACPA-positive than ACPA-
negative patients appeared to have AMH levels below
the 10th percentile. Furthermore, in the LMM, the
negative association of ACPA-positivity with serum
AMH levels was present, although non-significant,
which may have been due to the lower number of
subjects in this study. The present idea among rheu-
matologists is that ACPA-positive RA may be
a different disease than ACPA-negative RA. It is not
clear whether the reduced ovarian function is a result
of this probably different disease mechanism, or of
increased inflammatory damage due to longer periods
of high disease activity. However, the lower AMH
levels in patients who are ACPA-positive, fit with the
overall concept that ACPA-positive RA is a more
destructive disease with more extra-articular
manifestations.29
Table 1 Characteristics of women with rheumatoid arthritis who participated in the PARA study and had a follow-up assessment
in 2015/2016 (N=128)
Variables Variables
Age (years) Anti-rheumatic drugs at follow-up
At first visit 31.8±3.8 MTX 65 (51%)
At follow-up 42.6±4.4 Prednisone 16 (13%)
Sulfasalazine 15 (12%)
Age at menarche (years) 13.1±1.4 Hydroxychloroquine 17 (13%)
Missing 9 (7.0%) Leflunomide 5 (3.9%)
Smokers at first visit 9 (7.0%) Biologicals—total n (%) 71 (55%)
Missing 2 (1.6%) Etanercept 29 (23%)
Infliximab –
Disease characteristics Certolizumab 2 (1.6%)
Duration of disease (years) Adalimumab 20 (16%)
At first visit 4.8 (2.1–10.4) Golimumab 3 (2.3%)
At follow-up 15.8 (12.7–21.5) Abatacept 6 (4.7%)
Missing 1 (0.8%) Rituximab 2 (1.6%)
Presence of ACPA, n (%) 78 (61%) Tocilizumab 9 (7.0%)
Presence of RF, n (%) 85 (66%)
Presence of erosions, n (%) 77 (60%) Use of MTX
Missing 3 (2.3%) Ever used MTX 113 (88%)
Missing 2 (1.6%)
Hormone use at follow-up Cumulative duration of MTX use
None 62 (48%) Never used 13 (10%)
Oral contraceptive pill 25 (20%) Less than 1 year 12 (9.3%)
Levonorgestrel releasing IUD 37 (29%) 1 to 5 years 27 (21%)
Injectable progesterone 2 (1.6%) 5 to 10 years 31 (24%)
Missing 2 (1.6%) >10 years 25 (20%)
Missing 20 (16%)
Cumulative years MTX in users 5.8 (2.2–10.2)
ACPA, anti-citrullinated protein antibodies; IUD, intra-uterine device;MTX,methotrexate; PARA, pregnancy-induced amelioration of rheumatoid
arthritis; RF, rheumatoid factor.
Rheumatoid arthritis
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Otherwise, there may be a genetic basis for the compro-
mised ovarian function in RA. In genome-wide associa-
tion studies, not only genes linked to DNA repair and
genome maintenance have been related to age at meno-
pause, but also genes linked to immune response seem to
determine the timing of menopause.14 Whether RA and
early menopause share a common genetic basis, may be
the focus of future research.
The current study population was a more fertile selec-
tion of the original PARA study, represented by a lower
percentage of nulliparity in participants than in non-
participants. This is most likely due to the nature of the
original PARA study and its first follow-up studies, focus-
ing on pregnancy, childbirth, and the health of the chil-
dren born during the study. Regular newsletters
informed participants of the study outcomes. Several nul-
liparous women withdrew their consent for future
contact. It is assumed this is because of the emotional
burden of the regular reminders of their failure to
conceive.
Regarding generalisability, we should also consider the
recent changes in diagnosis and treatment of RA. Where
patients from the PARA cohort were classified as having
RA according to the 1987 ACR criteria,21 nowadays RA is
often recognised and diagnosed at an earlier stage, when
less damage has been done.30 Furthermore, new treat-
ment guidelines have been developed over the last dec-
ade, focusing on early combination therapy in a treat-to-
target regimen, and the addition of biological disease-
modifying antirheumatic drugs such as tumour necrosis
factor (TNF) inhibitors for a tighter disease
management.31 The next generation of young female
RA patients may therefore have a milder course of the
disease, with better long-term outcomes. Whether
Table 2 Comparison of participants and non-participants in the follow-up of the PARA study
Current study Non-participants P value
Number of unique patients n=128 n=167
Age§—years 42.5±4.4 43.4±4.1 0.055‡
Age at last PARA episode—years 32.0±3.9 32.8±3.9 0.11‡
Smoker during PARA study 9 (7%) 28 (17%) 0.013*
Missing 2 (2%) 4 (2%)
Number of episodes within PARA study
1 episode 98 (77%) 139 (83%)
2 episodes 24 (19%) 24 (14%)
3 episodes 6 (5%) 3 (2%)
4 episodes – 1 (1%)
Obstetric history
Never pregnant before PARA study 73 (57%) 93 (56%) 0.91*
Pregnant during last PARA episode 117 (91%) 120 (72%) <0.001*
Nulliparous at end of PARA study 6 (4.7%) 36 (22%) <0.001*
Disease Characteristics
Duration of RA§—years 15.6 (12.6–20.9) 15.5 (13.1–20.5) 0.88†
Missing – 2 (1%)
Duration of RA at first PARA episode 4.2 (2.0–9.6) 4.7 (1.9–8.5) 0.99†
Missing – 2 (1%)
Presence of ACPA 78 (61%) 112 (67%) 0.33*
Presence of RF 86 (67%) 125 (75%) 0.16*
Presence of erosions 77 (60%) 100 (60%) 0.61*
Missing 3 (2.3%) 9 (6.4%)
Disease activity Score (DAS28) during last PARA episode
Preconception 3.6±1.3 3.8±1.2 0.17‡
Missing 51(40%) 54 (32%)
First trimester 3.5±1.2 3.6±1.2 0.57‡
Missing 37 (29%) 70 (42%)
Last available DAS28 (non-pregnant) 3.5±1.2 3.5±1.2 0.79‡
Missing – 4 (2%)
*Fisher’s exact-test;
†Mann-Whitney U-test;
‡Student’s t test;
§At 1 January 2016.
PARA, pregnancy-induced amelioration of RA; RA, rheumatoid arthritis.
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ovarian function and reproductive performance will also
benefit from these changes, should be addressed in
future studies.
A possible limitation of our study is the use of hormonal
contraceptives. Fifty per cent of the current participants
used hormonal contraceptives during the follow-up
assessment, mainly progesterone releasing intra-uterine
devices, or the oral contraceptive pill (OCP). The effect
of exogenous steroid hormones on serum AMH levels is
still unclear, with several studies reporting no significant
Figure 2 First and last available serum anti-Müllerian hormone (AMH) levels (μg/L) in women with rheumatoid arthritis
who participated in the pregnancy-induced amelioration of rheumatoid arthritis (PARA) study and were visited again after
6.4–13.7 years. The lines represent the 10th, 50th and 90th percentiles of AMH values in healthy controls (Lie Fong 2012).
Table 3 Distribution of age-specific percentiles of serum AMH levels in women with rheumatoid arthritis from the PARA study,
grouped by serology and erosions
ACPA† RF† Erosions†,‡ Total group
Neg Pos Neg Pos No Yes
(n=50) (n=78) (n=43) (n=85) (n=48) (n=77) (n=128)
First AMH measurement
<P10 7 (14%) 13 (17%) 5 (12%) 15 (18%) 5 (10%) 15 (19%) 20 (16%)
P10–P50 18 (36%) 31 (40%) 14 (33%) 35 (41%) 17 (35%) 32 (42%) 49 (38%)
P50–P90 22 (44%) 30 (38%) 21 (49%) 31 (36%) 24 (50%) 26 (34%) 52 (51%)
>P90 3 (6.0%) 4 (5.1%) 3 (7.0%) 4 (4.7%) 2 (4.2%) 4 (5.2%) 7 (5%)
Last AMH measurement
<P10 15 (30%) 35 (45%) 12 (28%) 38 (45%) 15 (31%) 34 (44%) 50 (39%)
P10–P50 10 (20%) 17 (22%) 6 (14%) 21 (25%) 11 (23%) 16 (21%) 27 (21%)
P50–P90 23 (46%) 20 (26%) 20 (47%) 23 (27%) 21 (44%) 20 (26%) 43 (34%)
>P90 1 (2.0%) 4 (5.1%) 2 (4.7%) 3 (3.5%) 1 (2.1%) 4 (5.2%) 5 (4%)
NA 1 (2.0%) 2 (2.6%) 3 (7.0%) – – 3 (3.9%) 3 (2%)
†At baseline.
‡The presence or absence of erosions were missing for n=3 subjects.
ACPA, anti-citrullinated protein antibodies; AMH, anti-Müllerian hormone; PARA, pregnancy-induced amelioration of RA; RF, rheumatoid factor.
Values are given as n(%).
Rheumatoid arthritis
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effect of exogenous hormones on serum AMH levels,
whereas other studies have shown lower AMH levels in
users of either OCPs or progesterone-only pills.32–34 Sen-
sitivity analyses excluding women using any of these hor-
mones, still showed one-third of patients having AMH
levels below the 10th percentile at follow-up. Therefore,
the current use of contraceptives could not explain the
decreased long-term serum AMH levels in our study
group compared with controls.
Several other factors may affect serumAMH levels, such
as smoking and body mass index (BMI). Studies on the
effect of smoking on AMH levels report varying results,
ranging from no effect35 36 to decreased AMH level in
smoking subjects.37 In both the control group and the
most recent subject assessments, the smoking status was
not assessed. The percentage of smokers among the stu-
died patients was low during the original PARA study, and
therefore the impact of smoking on the study results is
expected to be minimal.
A higher BMI is associated with lower serum AMH
levels.38 BMI was not recorded for the women included
in the PARA study, but as reported previously, themedian
BMI for women 18–42 years in a representative Dutch RA
cohort was 24.2 (21.9–28.3).17 Therefore, we assume that
the lower AMH levels in the current study are not attrib-
uted to higher BMI values.
Both in the patient and the control group, blood sam-
pling was done irrespective of the menstrual cycle day.
Fluctuations of serum AMH levels in different phases of
the menstrual cycle may be present. Since especially in
the lower range of AMH levels cycle fluctuations are not
considered to be clinically relevant,39–41 no significant
effect on the study results are to be expected.
AMH levels in this study were measured with an ultra-
sensitive picoAMH assay, whereas the original control
samples were not available for reassessment with this
assay. The comparison of AMH levels between patients
and controls should be considered with caution, since the
conversion factor applied to the controls has been devel-
oped in another laboratory than the laboratory that per-
formed the measurements with the new assay. Inaccuracy
due to the conversion, may give deviating results.25
Furthermore, the currently applied picoAMH assay has
a lower limit of detection compared with the Gen II assay
that was used for the AMH measurements in controls.
Nevertheless, adjusting the very low values in the current
patients to the LoD applied in the controls, still resulted
in a significantly higher percentage of patients with AMH
values below the 10th percentile of controls.
New research questions arise from this study. Future
research should focus on the effect of more severe dis-
ease, such as in ACPA-positive RA patients, on serum
AMH levels. This may be elucidated in larger studies.
Furthermore, studying the effect of chronic inflamma-
tion on ovarian histology in women with active RA may
point towards causal mechanisms of the current findings.
For daily practice, it is important to realise that ovarian
function and women’s health are strongly related. Several
studies demonstrate the relation of decreasing AMH
levels with the occurrence of natural menopause.42–45
Inaccuracy in the individual predictions remains, and
therefore AMH measurements are currently only applic-
able for predictions on group level.46 Nonetheless, this
study demonstrates an early decline in ovarian function in
women with RA, possibly strongest in women with more
severe disease. Rheumatologists should be aware of the
adverse health effects of early menopause. Anti-
rheumatic treatment should aim for suppression of dis-
ease activity to prevent health problems resulting from
possible early menopause. Furthermore, in women
Table 4 Estimates of linear-mixedmodel describing the change of serum anti-Müllerian hormone (AMH) levels (applying square
root transformation) with increasing age in 128 female RA patients
Variable Estimate SE 95% CI
(Intercept) 4.648 0.350 3.962 to 5.334
Biological age—per year† −0.077 0.007 −0.090 to −0.063§
Disease duration‡ 0.015 0.031 −0.046 to 0.076
Presence of ACPA‡ −0.544 0.349 −1.227 to 0.140
Presence of erosions‡ −0.076 0.239 −0.545 to 0.393
Presence of RF‡ −0.312 0.281 −0.863 to 0.239
Ever used MTX 0.005 0.187 −0.361 to 0.372
Age*disease duration −0.001 0.001 −0.002 to 0.001
ACPA*erosions 0.364 0.447 −0.512 to 1.239
ACPA*RF 0.413 0.441 −0.451 to 1.276
Erosions*RF −0.146 0.390 −0.910 to 0.618
ACPA*erosions*F −0.121 0.573 −1.243 to 1.001
†Age is used as time variable in the model.
‡Variable at baseline.
§P<0.05.
ACPA, snti-citrullinated protein antibodies; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor.
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displaying symptoms of early menopause, referral to
a gynaecologist is advised.
In conclusion, serum AMH levels show a faster decline
over time in women with RA compared with healthy con-
trols, supporting the idea that in chronic inflammatory
conditions, the body is less fit for reproduction. Optimal
treatment of chronic inflammatory disease in an early
phase may improve long-term women’s health.
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